RGEN News and Press, Repligen Corporation From 08/12/21

Horizon Therapeutics has now reached a growth point that is supportive of long-term success due to multiple eggs in the basket. The company has 11 FDA approved drugs and 10 phase 2 or 3 clinical trials underway, with revenue growth currently averaging 91% per year over the past 10 yea...

Repligen (RGEN) makes equipment for use in the production cycle of biological pharmaceuticals, from cell cultures through purification (called chromatography) to the formulation of vaccines, explains Mike Cintolo, growth stock expert and editor of Cabot Top Ten Trader. For further details s...

The Street expected a strong quarter from Danaher, and they got that and more, with strong growth across the business and significant margin leverage. Bioproduction remains a once-in-a-generation growth opportunity where Danaher has bought its leadership, including the recent deal for...

Repligen is one of those prime companies that let you sleep well at night with a long history of stable performance. The company has shown 30% revenue growth over the past decade, and will lift the trend beyond that over the next few years. I recommend this company to be added to ...

Shares of Repligen (NASDAQ: RGEN) were up by 14.8% this week as of the market close on Thursday. Those gains came after the company reported its second-quarter results on Tuesday and increased its full-year revenue and earnings guidance. Repligen announced Q2 revenue of $163 mil...

Are These The Best Health Care Stocks To Buy As We Head Into August? Health care stocks have been popular among investors in the stock market over the past year. As we continue to combat coronavirus and its variants, health care services remain an essential service. Recently, th...

Image source: The Motley Fool. Repligen Corp (NASDAQ: RGEN) Q2 2021 Earnings Call Jul 27, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Repligen Corp (RGEN) Q2 2021 Earnings Call Transcript

Repligen Corp, Inc. (RGEN) Q2 2021 Earnings Conference Call July 27, 2021, 08:30 ET Company Participants Sondra Newman - Global Head, IR Anthony Hunt - CEO, President & Director Jon Snodgres - CFO Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company Puneet Souda - SV...

Repligen (RGEN) shares rise nearly 3% premarket after the company posted second-quarter results that beat Wall Street estimates, and raised its full-year forecast.The company's quarterly revenue rose 86% to $162.96M, beating analysts' average estimate by $18.72M.Chief executive...

Repligen (RGEN): Q2 Non-GAAP EPS of $0.79 beats by $0.27; GAAP EPS of $0.64 beats by $0.23.Revenue of $162.96M (+86.3% Y/Y) beats by $18.72M.Adjusted EBITDA of $59.67M vs. consensus of $43.4M.Shares +1.9% PM.Press Release For further details see: Repligen EPS beats by $0.27, beats on re...